isotschimgine

farnesoid X receptor agonist

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

1.	Non-alcoholic Fatty Liver Disease 06/01/2021 - "Isotschimgine alleviates nonalcoholic steatohepatitis and fibrosis via FXR agonism in mice." 06/01/2021 - "We identified previously that isotschimgine (ITG) is a non-steroidal FXR selective agonist and has potent therapeutic effects on NAFLD in mice. "
2.	Obesity 01/01/2020 - "Here we demonstrate that isotschimgine (ITG), a constituent in genus Ferula, as a novel FXR agonist with anti-obesity and anti-hepatic steatosis effects. " 01/01/2020 - "Identification of isotschimgine as a novel farnesoid X receptor agonist with potency for the treatment of obesity in mice."
3.	Fibrosis (Cirrhosis) 06/01/2021 - "Isotschimgine alleviates nonalcoholic steatohepatitis and fibrosis via FXR agonism in mice."

1.	Therapeutic Uses